ThromboGenics names new CEO
ThromboGenics' current COO Patrik De Haes has been appointed to succeed Professor Désiré Collen as the company's new CEO. No specific reasons were given for the change, but Collen--who founded the company--will remain on the ThromboGenics' board of directors. De Haes will also be appointed to the board, and assumes his role as CEO on September 1.
- here's ThromboGenics' release
Related Articles:
Positive data paves way for ThromboGenics trial
ThromboGenics touts Phase II eye therapy results
Comments